STOCK TITAN

AVITA Medical (NASDAQ: RCEL) adopts yearly say-on-pay advisory schedule

(Neutral)
(Neutral)
Form Type
8-K/A

Rhea-AI Filing Summary

AVITA Medical, Inc. disclosed its decision on how often to seek stockholder advisory approval of executive compensation following its June 3, 2026 annual meeting. Stockholders supported holding say-on-pay votes every year, with 9,545,151 votes for 1 year, 924,743 for 2 years, 650,252 for 3 years, 581,759 abstentions, and 3,890,542 broker non-votes.

Consistent with this outcome and the board’s recommendation, the board determined that AVITA Medical will hold future advisory votes on named executive officer compensation every year until the next required frequency vote, which will occur no later than the company’s 2032 annual meeting of stockholders.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for 1-year frequency 9,545,151 Advisory vote on executive compensation frequency at 2026 annual meeting
Votes for 2-year frequency 924,743 Advisory vote on executive compensation frequency at 2026 annual meeting
Votes for 3-year frequency 650,252 Advisory vote on executive compensation frequency at 2026 annual meeting
Abstentions 581,759 Advisory vote on executive compensation frequency at 2026 annual meeting
Broker Non-Votes 3,890,542 Advisory vote on executive compensation frequency at 2026 annual meeting
Next required frequency vote year 2032 Next required advisory vote on frequency of say-on-pay
non-binding advisory vote regulatory
"Stockholders voted in favor of the non-binding advisory vote to set the frequency"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
Broker Non-Votes regulatory
"Abstentions | Broker Non-Votes | 581,759 | 3,890,542"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company Explanatory Note"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What decision did AVITA Medical (RCEL) make about say-on-pay vote frequency?

AVITA Medical chose to hold annual advisory votes on executive compensation. This follows a stockholder vote supporting a 1-year frequency and will apply until the next required frequency vote, due no later than the 2032 annual meeting.

How did AVITA Medical (RCEL) stockholders vote on a 1-year say-on-pay frequency?

Stockholders cast 9,545,151 votes in favor of holding say-on-pay votes every year. This was the highest-supported option and aligned with the board’s recommendation on executive compensation vote frequency.

What were the vote totals for 2- and 3-year say-on-pay options at AVITA Medical (RCEL)?

The 2-year option received 924,743 votes, and the 3-year option received 650,252 votes. These totals were lower than the support for annual votes, which guided the board’s decision to adopt a 1-year frequency.

How many abstentions and broker non-votes occurred in AVITA Medical’s (RCEL) frequency vote?

There were 581,759 abstentions and 3,890,542 broker non-votes on the frequency of say-on-pay votes. These shares did not support a specific frequency option but are reported as part of the overall voting results.

When will AVITA Medical (RCEL) next hold a vote on say-on-pay frequency?

The next required advisory vote on the frequency of say-on-pay votes will occur no later than AVITA Medical’s 2032 annual meeting. Until then, the company plans to hold advisory compensation votes every year.
true000176230300017623032026-06-032026-06-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 03, 2026

 

 

AVITA Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39059

85-1021707

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

28159 Avenue Stanford

Suite 220

 

Valencia, California

 

91355

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 661 367-9170

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RCEL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Explanatory Note

This Current Report on Form 8-K/A (this "Amendment") amends the Current Report on Form 8-K filed by AVITA Medical, Inc. (the "Company") with the Securities and Exchange Commission on June 4, 2026 (the "Original Form 8-K"), which reported, among other things, the voting results of the Company's Annual Meeting of Stockholders held on June 3, 2026 (the "Meeting"). The sole purpose of this Amendment is to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company’s decision regarding how frequently it will conduct future stockholder advisory votes to approve the compensation of the Company’s named executive officers. No other changes have been made to the Original Form 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.

As previously disclosed in the Original Form 8-K, at the Meeting the Company's stockholders cast the following votes on an advisory basis regarding the frequency of future advisory votes on the compensation of the Company's named executive officers:

 

8.
Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13): Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

 

Votes For

 

 

 

 

 

1 Year

 

2 Years

 

3 Years

 

Abstentions

 

Broker Non-Votes

 

 

9,545,151

 

 

924,743

 

 

650,252

 

 

581,759

 

 

3,890,542

 

 

 

Consistent with the recommendation of the Company's Board of Directors and the option receiving the highest number of votes cast by the Company's stockholders, the Board of Directors has determined that the Company will hold future advisory votes on the compensation of its named executive officers every year until the next required advisory vote on the frequency of such votes, which will occur no later than the Company's 2032 Annual Meeting of Stockholders.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AVITA Medical, Inc.

 

 

 

 

Date:

August 6, 2026

By:

/s/ David O’Toole

 

 

 

David O’Toole
Chief Financial Officer

 


Filing Exhibits & Attachments

1 document